Cormorant Asset Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cormorant Asset Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,500	Closed	-$2.43M	–	105
2021 Q2	$2.43M	Sell	9,500 -3,833	-29%	-$957K	0.08%	92
2021 Q1	$3.54M	Hold	13,333	–	–	0.08%	102
2020 Q4	$4.92M	Sell	13,333 -1,651	-11%	-$474K	0.12%	85
2020 Q3	$3.66M	Sell	14,984 -8,349	-36%	-$2.6M	0.14%	81
2020 Q2	$6.72M	Sell	23,333 -3,838	-14%	-$1.13M	0.26%	67
2020 Q1	$5.54M	Sell	27,171 -609	-2%	-$194K	0.26%	57
2019 Q4	$12.4M	Sell	27,780 -5,483	-16%	-$1.95M	0.5%	49
2019 Q3	$10.2M	Sell	33,263 -5,070	-13%	-$1.65M	0.62%	45
2019 Q2	$12.2M	Buy	+38,333	New	+$13.3M	0.7%	41

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return

Cormorant Asset Management's EIGR Position: Q3 2021 in Review

Cormorant Asset Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2021, closing a stake of 9,500 shares — an estimated $2.43M sold.

Cormorant Asset Management first reported a position in EIGR in Q2 2019 and held it in 9 quarters. The position peaked at $12.4M in Q4 2019. 92 funds tracked by Wall St. Rank hold EIGR as of Q3 2021.

Cormorant Asset Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Cormorant Asset Management sold 9,500 Eiger BioPharmaceuticals, Inc. shares in Q3 2021, an estimated $2.43M.
Cormorant Asset Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 9 quarters.
Cormorant Asset Management's Eiger BioPharmaceuticals, Inc. position peaked at $12.4M in Q4 2019.
92 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2021.

Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.